Parodi Alessandro, Davì Sergio, Pringe Alejandra Beatriz, Pistorio Angela, Ruperto Nicolino, Magni-Manzoni Silvia, Miettunen Paivi, Bader-Meunier Brigitte, Espada Graciela, Sterba Gary, Ozen Seza, Wright Dowain, Magalhães Claudia Saad, Khubchandani Raju, Michels Hartmut, Woo Patricia, Iglesias Antonio, Guseinova Dinara, Bracaglia Claudia, Hayward Kristen, Wouters Carine, Grom Alexei, Vivarelli Marina, Fischer Alberto, Breda Luciana, Martini Alberto, Ravelli Angelo
Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genoa, Italy.
Arthritis Rheum. 2009 Nov;60(11):3388-99. doi: 10.1002/art.24883.
To describe the clinical and laboratory features of macrophage activation syndrome as a complication of juvenile systemic lupus erythematosus (SLE).
Cases of juvenile SLE-associated macrophage activation syndrome were provided by investigators belonging to 3 pediatric rheumatology networks or were found in the literature. Patients who had evidence of macrophage hemophagocytosis on bone marrow aspiration were considered to have definite macrophage activation syndrome, and those who did not have such evidence were considered to have probable macrophage activation syndrome. Clinical and laboratory findings in patients with macrophage activation syndrome were contrasted with those of 2 control groups composed of patients with active juvenile SLE without macrophage activation syndrome. The ability of each feature to discriminate macrophage activation syndrome from active disease was evaluated by calculating sensitivity, specificity, and area under the receiver operating characteristic curve.
The study included 38 patients (20 with definite macrophage activation syndrome and 18 with probable macrophage activation syndrome). Patients with definite and probable macrophage activation syndrome were comparable with regard to all clinical and laboratory features of the syndrome, except for a greater frequency of lymphadenopathy, leukopenia, and thrombocytopenia in patients with definite macrophage activation syndrome. Overall, clinical features had better specificity than sensitivity, except for fever, which was highly sensitive but had low specificity. Among laboratory features, the best sensitivity and specificity was achieved using hyperferritinemia, followed by increased levels of lactate dehydrogenase, hypertriglyceridemia, and hypofibrinogenemia. Based on the results of statistical analysis, preliminary diagnostic guidelines for macrophage activation syndrome in juvenile SLE were developed.
Our findings indicate that the occurrence of unexplained fever and cytopenia, when associated with hyperferritinemia, in a patient with juvenile SLE should raise the suspicion of macrophage activation syndrome. We propose preliminary guidelines for this syndrome in juvenile SLE to facilitate timely diagnosis and correct classification of patients.
描述巨噬细胞活化综合征作为青少年系统性红斑狼疮(SLE)并发症的临床和实验室特征。
青少年SLE相关巨噬细胞活化综合征病例由3个儿科风湿病网络的研究人员提供或从文献中获取。骨髓穿刺有巨噬细胞噬血细胞现象证据的患者被认为患有明确的巨噬细胞活化综合征,无此类证据的患者被认为患有可能的巨噬细胞活化综合征。将巨噬细胞活化综合征患者的临床和实验室检查结果与由无巨噬细胞活化综合征的活动性青少年SLE患者组成的2个对照组进行对比。通过计算敏感性、特异性和受试者操作特征曲线下面积,评估每个特征区分巨噬细胞活化综合征与活动性疾病的能力。
该研究纳入了38例患者(20例患有明确的巨噬细胞活化综合征,18例患有可能的巨噬细胞活化综合征)。明确和可能的巨噬细胞活化综合征患者在该综合征的所有临床和实验室特征方面具有可比性,但明确的巨噬细胞活化综合征患者淋巴结病、白细胞减少和血小板减少的发生率更高。总体而言,临床特征的特异性优于敏感性,但发热除外,发热敏感性高但特异性低。在实验室特征中,血清铁蛋白升高的敏感性和特异性最佳,其次是乳酸脱氢酶水平升高、高甘油三酯血症和低纤维蛋白原血症。基于统计分析结果,制定了青少年SLE中巨噬细胞活化综合征的初步诊断指南。
我们的研究结果表明,青少年SLE患者出现不明原因发热和血细胞减少并伴有血清铁蛋白升高时,应怀疑巨噬细胞活化综合征。我们提出了青少年SLE中该综合征的初步指南,以促进患者的及时诊断和正确分类。